Akebia Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Akebia Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Akebia Therapeutics Inc Strategy Report
- Understand Akebia Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Akebia Therapeutics Inc (Akebia Therapeutics) is a commercial-stage biopharmaceutical company. It develops and commercializes novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. The company’s product portfolio includes vadadustat, a hypoxia-inducible factor (HIF) prolyl hydroxylase that treats dialysis-dependent chronic kidney disease (DD-CKD) and non-dialysis-dependent chronic kidney disease (NDD-CKD); ferric citrate targeting hyperphosphatemia and iron deficiency anemia; AKB-9090 for acute kidney injury and acute respiratory distress syndrome; and AKB-10108, that treats retinopathy of prematurity. It operates through its subsidiaries in the US, Ireland and the UK. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Akebia Therapeutics Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Vadadustat: | Auryxia |
Dialysis-Dependent Chronic Kidney Disease | Vafseo |
Non-Dialysis Dependent Chronic Kidney Disease | Akebia Therapeutics |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Financing Agreements | In January, the company secured US$55 million loan from funds and accounts managed by BlackRock. |
2023 | Regulatory Approval | In June, the company announced that Swiss Agency for Therapeutic Products granted marketing authorization for Vafseo. |
2023 | Contracts/Agreements | In May, the company entered into an agreement with MEDICE Arzneimittel Pütter GmbH&Co.KG for the commercialization of Vafseo for the treatment of anemia associated with CKD in Europe and Australia. |
Competitor Comparison
Key Parameters | Akebia Therapeutics Inc | Johnson & Johnson | Pfizer Inc | Sanofi | GSK plc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | France | United Kingdom |
City | Cambridge | New Brunswick | New York | Paris | Brentford |
State/Province | Massachusetts | New Jersey | New York | Ile-de-France | England |
No. of Employees | 167 | 131,900 | 88,000 | 87,994 | 70,212 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Adrian Adams | Chairman | Executive Board | - | 73 |
John P. Butler | Chief Executive Officer; Director; President | Executive Board | 2013 | 59 |
Michel Dahan | Senior Vice President; Chief Operating Officer | Senior Management | 2013 | 45 |
Nicole R. Hadas | Secretary; Senior Vice President; Chief Legal Officer | Senior Management | 2013 | 51 |
Meredith Bowman | Chief People Officer; Senior Vice President - People | Senior Management | 2016 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer